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We analyzed data from historical controls treated with meglumine antimoniate to compare the frequency of
adverse events observed in patients with cutaneous leishmaniasis treated with the same dose of meglumine antimoniate
contaminated with heavy metals in an endemic area of the State of Bahia, Brazil. Group A patients were treated in
2000 with the drug produced by Eurofarma Laboratórios Ltda., São Paulo, Brazil (lot A) and group B patients were
treated in 1996 with the reference drug produced by Rhodia Farma Ltda., São Paulo, Brazil (lot B). We observed an
unusual higher frequency of skin reactions in group A patients. However, all type of adverse events observed in
group A were also observed in group B.  The physico-chemical analysis of these lots revealed that lot A had lower pH
and higher concentration of total and trivalent antimony, lead, cadmium, and arsenic. Our findings suggest that the
skin reactions could be attributed to heavy metal contamination of lot A.
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Pentavalent antimonials had been, for many years, the
first-choice drugs for the treatment of leishmaniasis
(Marsden 1985, Herwaldt & Berman 1992, Berman 1997).
Two salts are commercially available, meglumine
antimoniate and sodium stibogluconate. They are used
by the IM or IV route. In Brazil, patients with cutaneous
leishmaniasis are treated with meglumine antimoniate, 10-
20 mg/kg/day IM or IV, for 20-30 days following the rec-
ommendations of the Brazilian Ministry of Health. The
drug usually causes mild to moderate adverse events that
rarely lead to treatment suspension. Myalgias, arthralgias,
abdominal symptoms, headache, elevation of aminotrans-
ferases and amylase, and electrocardiographic changes
affecting the ST segment and QTc are the most frequent
events (Marsden 1985, Ballow et al. 1987, Franke et al.
1990, Gasser et al. 1994, Berman 1997). Rarely, severe tox-
icity is observed such as acute renal and hepatic failure
(Kopke et al. 1993), thrombocytopenia (Hepburn 1993) and
even sudden death, probably due to cardiac rhythm dis-
turbances (Chulay et al. 1985).  The presence of trivalent
antimony contaminating pentavalent antimonials for clini-
cal use was demonstrated and could explain the toxic
events observed during treatment (Franco et al. 1995).
Pharmacokinetics of both drugs is comparable and it is
assumed that they produce similar therapeutic effects
(Chulay et al. 1988). Toxicity caused by antimonials could
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be different for each drug and formal comparisons of so-
dium stibogluconate and meglumine antimoniate are
scarce. We recently compared the efficacy, safety and
toxicity of sodium stibogluconate produced in China (so-
dium stibogluconate BP88 Shandong, Xinhua, China)
with meglumine antimoniate (Rhodia Farma, Ltda., São
Paulo, Brazil) and our conclusions suggest that sodium
stibogluconate was more toxic than the drug produced
by Rhodia Farma Ltda. (Saldanha et al. 1999, 2000). There
are no definite criteria to evaluate the quality of antimoni-
als. High osmolarity could be a marker of higher toxicity
as shown by one report from India (Sundar et al. 1998).
We had measured the osmolarity and pH of different lots
of meglumine antimoniate and that physico-chemical prop-
erties appear to be stable at least during a three-year pe-
riod (Romero et al. 1996).   The presence of metals such as
lead has been reported as a cause of poisoning in pa-
tients treated with traditional Chinese remedies (Wu et al.
1996) but there is little information about this kind of con-
tamination in pharmaceutical products (Popinska et al.
1999). Flores et al. (2000) drew attention to the fact that
routine quality control of drugs with the appropriate meth-
ods to detect heavy metals has been traditionally ne-
glected.   Contamination of antimonials with heavy metals
such as lead, arsenic and cadmium is not expected unless
poor quality control of manufacturing process allows the
use of impure salts.  We use historical controls (patients
with cutaneous leishmaniasis) treated with the unique lot
of the reference drug, meglumine antimoniate (Rhodia
Farma Ltda., São Paulo, Brazil) in 1996 to compare the
frequency of unusual adverse events due to meglumine
antimoniate (Eurofarma Laboratórios Ltda., São Paulo,
Brazil) used in patients with similar conditions in 2000.
We compared the physico-chemical properties of both
drugs raising the hypothesis of toxicity attributed to heavy
metal contamination.
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PATIENTS AND METHODS
Patients - Nineteen patients (Group A) with localized
cutaneous leishmaniasis (LCL) were treated with
meglumine antimoniate (Eurofarma Laboratorios Ltda.,
São Paulo, Brazil), 20 mg/kg/day I. V. for 20 days (Lot A).
They were included in a therapeutic protocol aiming the
identification of prognostic factors associated with fail-
ure to cure from August through December 2000. Lot A
was produced for the Brazilian Ministry of Health and
correspond to a unique lot No. 011/00 A, valid through
May 2002. Patients were provided with disposable sy-
ringes and instructed to return every 10 days during treat-
ment and monthly thereafter for a three months period to
diagnose failure or cure.  Data from group A was com-
pared with data from 54 historical controls (Group B)
treated and followed in a similar manner by the same re-
searcher in 1996 with a unique lot of meglumine
antimoniate, No. 0595 L061 (Rhodia Farma Ltda, São Paulo,
Brazil) (Lot B) in a protocol designed to compare the char-
acteristics of two species of the Viannia subgenus
(Romero et al. 2001a, b). Lot B was valid through May
2000.  Both groups attended the basic health unit of Corte
de Pedra District, Presidente Tancredo Neves municipal-
ity, State of Bahia, Brazil, located in an endemic area of
Leishmania (Viannia) braziliensis (França et al. 1991).
All patients had positive Montenegro skin test performed
as recommended by the World Health Organization (WHO
1984) using antigen prepared as described by Reed et al.
(1986). All cases had confirmed parasitological diagnosis
using the isolation and visualization methods previously
described (Romero et al. 2001a). Both research protocols
were done in agreement with the Helsinki Declaration and
the Resolution 196/96 of the National Health Council of
the Ministry of Health of Brazil, which regulates research
in humans. The Ethics Research Committee of the Univer-
sity of Brasília approved the protocols. All patients signed
informed consents to diagnostic tests and were treated in
accordance to the recommendations of the Brazilian Min-
istry of Health. When the protocol was interrupted be-
cause the unusual frequency of adverse events all pa-
tients were informed of the potential causes of the phe-
nomenon and instructed to stop medication and report
any symptom related to the treatment.
Chemical analysis - All measurements were carried
out at the same time in 2001 with an atomic absorption
spectrometer Model 3030 B (Perkin Elmer, Germany)
equipped with a continuum source background correc-
tion system. Equipment was coupled to an electrothermal
atomizer (longitudinally heated graphite tube, Model HGA-
400, Perkin Elmer) or to a batch hydride generation sys-
tem (MHS-10, Perkin Elmer). Antimony determinations
were performed after water dilution of samples using an
air/acetylene flame (217.6 nm) and pneumatic nebuliza-
tion. Determinations of arsenic (193.7 nm), cadmium (228.8
nm) and lead (283.3 nm) were performed by electrothermal
atomization using a graphite tube with a specific heating
programme (drying, pyrolysis and atomization) for each
element. Argon (99.996%, White-Martins, Brazil) was used
as protection gas. Integrated absorbance was used in-
stead of peak height for measurements.
Determination of antimony on the trivalent state in
the samples was performed by hydride generation atomic
absorption spectrometry using a flame heated quartz cell
as atomizer. Samples were diluted with water using 4%
(m/v) tartaric acid solution as selective medium for triva-
lent antimony determination. Reductant was a daily pre-
pared 1%, m/v, sodium tetrahydroborate solution. Refer-
ence trivalent antimony solutions were daily prepared and
absorbance signals were completely recorded in 15 sec.
Argon was used as purge gas and measurements were
made in integrated absorbance mode.
All chemicals used were of analytical reagent grade
from Merck (Darmstadt, Germany). Distilled and double-
deionized water (maximum conductivity of 1.2 µS/cm) was
used to prepare all solutions. All glass apparatus were
soaked in 0.72 mol/l nitric acid, and thoroughly washed
with water before use. Working reference solutions were
prepared immediately before use by serial dilution from a
stock solution containing 1,000 mg/l for each element. All
determinations were made in triplicate from five test
samples for each individual lot. pH was measured with a
digital apparatus (Model 10, CELM, Brazil) in 10 ampoules,
one measure for each ampoule. The final mean for each lot
corresponds to the mean of 10 ampoules.
Osmolarity - This property was measured with a digi-
tal Fiske Osmometer (Fiske Associates, Norwood, MA,
USA) in 10 ampoules of each lot, obtaining three inde-
pendent measures for each ampoule for a mean estimate.
The mean for each lot was obtained using the mean val-
ues of the ten ampoules.
Statistical analysis - The comparisons of the fre-
quency of the observed adverse events were performed
with the chi-square test or Fisher exact test and the medi-
ans were compared with the Mann-Whitney-U test using
the Statistical Package for Social Science, version 9.0, 95%
confidence intervals were calculated using the EPI Info,
version 6.04.
RESULTS
Both groups were comparable by age, sex and total
body weight. Most patients were agricultural workers.
Table I shows the characteristics of the disease and the
results of the Montenegro skin test observed in both
groups. Table II shows the frequency of adverse events
observed in each group. Although the absolute propor-
tion of patients who experiences at least one adverse event
was similar between groups, the quality of the observed
events was different mainly due to the unusual higher
frequency of skin reactions in group A patients.
Arthralgias were more frequently observed in group B.
The episodes of skin reactions were characterized by the
onset of erithematous and itching plaques at the site of
the intravenous injections in the forearms and the ap-
pearance of generalized morbiliform rash during a sec-
ondary stage. Symptoms disappeared 3 to 14 days after
the interruption of the medication. Some patients needed
antihistaminic medication to improve itching. All patients
with skin reactions in group A were instructed to stop
treatment.  The patient in group B who experienced a skin
reaction had a generalized rash without any plaques on
the 19th day of treatment and consulted on the 20th day
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after the administration of the last prescribed dose and
her symptoms relief during the next five days.    Table III
shows the physico-chemical characteristics in the samples
of the lots used by each group. Lot A was characterized
by lower pH and osmolarity and higher concentrations of
total and trivalent antimony, lead, cadmium and arsenic.
The total concentration of antimony was 22% higher than
the expected concentration of 85mg/ml indicated by the
manufacturer.
DISCUSSION
Our data showed that the frequency of skin reaction,
an unusual adverse event, was higher in patients treated
with the drug containing a high concentration of lead,
cadmium and arsenic. Although historical controls had
limitations for comparisons in our case the therapeutic
protocols were identical and the same researcher was re-
sponsible for the adverse events monitoring and follow-
up. Furthermore the chemical analysis was performed at
the same time to avoid variations in the assay sensitivity.
We storage samples of the lot B used to treat the histori-
cal controls avoiding exposure to light at room tempera-
tures. We do not perform biochemical and electrocardio-
graphic tests to identify other kind of effects such as
cardiac, hepatic and pancreatic toxicity but it would be
expected a higher level of cardiac abnormalities since pa-
tients received also a higher dose of total and trivalent
antimony that have shown a dose dependent toxicity on
the heart (Chulay et al. 1985).  The type of the skin reac-
tions observed in group A patients could be attributed
initially to local sensitization with contaminant heavy
metals with posterior generalized rash. Arsenic, lead and
cadmium have been described as causes of contact al-
lergy (Cavelier & Foussereau 1995). Pentavalent antimony
could cause generalized rash but the phenomenon is rare
even with prolonged courses of the maximum recom-
mended dose (Franke et al. 1994).  In our case it appears to
be more plausible the hypothesis of reactions due to ar-
senic, lead or cadmium. The concentration of total and
trivalent antimony was higher in lot A. The trivalent spe-
cies is considered more toxic and more active than the
pentavalent form but patients usually tolerate high anti-
mony doses and rarely develop skin reactions.
Mean osmolarity levels in both lots was in the ex-
pected range of values based in our experience measur-
TABLE I
Clinical findings observed at entry time in two groups of
patients with cutaneous leishmaniasis treated with different
lots of meglumine antimoniate in Brazil a
Clinical finding Group A b Group B c Statistical
n=19 n=54 significance d
Age-years 21.5 22.0 0.505
(median) (14.0-32) (17.0-31.0)
Sex (male) 10/19 (52.6) 40/54 (74.1) 0.084
Number of lesions 1 1 0.840
(median) (1-2) (1-2)
Total body weight-kg 50.0 52.0 0.816
(median) (45.0-59.0) (42.8-60.3)
Total ulcerated 2.33 1.37 0.152
area-cm2 (median) (1.22-5.42) (1.02-2.86)
Disease duration- 4.0 4.0 0.458
weeks (median) (3.0-6.0) (2.0-12.0)
Montenegro skin 16.0 18.0 0.549
test-mm (median) (14.0-20.2) (14.0-2.0)
a: numbers in parenthesis are 25-75 quartiles for medians and %
for proportions; b: group A received meglumine antimoniate, lot
011/00 A (Eurofarma Laboratórios, Ltda., São Paulo, Brazil); c:
group B received meglumine antimoniate, lot  0595L061, (Rhodia
Farma, São Paulo, Brazil); d: statistical significance corresponds
to Mann-Whitney U test except for the proportion of male sex
comparison that was performed using Chi square test
TABLE II
Comparison of adverse events observed in two groups of
patients with cutaneous leishmaniasis treated with different
lots of meglumine antimoniate in Brazil
Adverse event Group A a Group B b Statistical
n = 19  (%)  n = 54  (%) significance c
Mylagias 5 (26.3) 13 (24.1)   1.000
Arthralgias 2 (10.5) 19 (35.2)   0.045
Anorexia 2 (10.5) 14 (25.9)   0.210
Headache 2 (10.5) 11 (20.4)   0.492
Fever 3 (15.8) 16 (29.6)   0.363
Rash 7 (36.8) 1 (1.9) < 0.001
Fatigue 2 (10.5) 2 (3.7)   0.276
Stop work d 2 (10.5) 4 (7.4)   0.647
Any adverse event 14 (73.7) 36 (66.7)   0.571
a: group A received meglumine antimoniate, lot 011/00 A
(Eurofarma Laboratórios, Ltda., São Paulo, Brazil); b: group B
received meglumine antimoniate, lot  0595L061 (Rhodia Farma,
São Paulo, Brazil); c: statistical significance corresponds to Fisher
exact test except for comparisons of the categories: arthralgias
and any adverse event that were performed with the Chi square
test; d: proportion of individuals who stopped normal activities
TABLE III
Physico-chemical characteristics of two lots of meglumine
antimoniate used for treatment of patients with cutaneous
leishmaniasis in Brazil a
Characteristic Lot A b Lot B c
PH 4.5 (0.05) 6.7 (0.05)
[4.48-4.56] [6.78-6.83]
Osmolarity (mosm/l) 708.9 (5.86) 959.3 (22.44)
[704.7-713.1] [952.5-965.7]
Total antimony (Sb III + SbV) 103.9 (1.4) 88.1 (1.2)
(mg/ml)
Trivalent antimony (mg/ml) 3.45 (0.31) 1.82 (0.25)
Heavy metals
Lead (mg/l) 52.71 (1.29) < 0.20
Arsenic (mg/l) 35.79 (1.54) < 0.90
Cadmium (mg/l) 0.132 (0.014) < 0.04
a: numbers in parenthesis correspond to SD. Numbers in brackets
correspond to 95% CI; b: meglumine antimoniate, lot  011/00 A
(Eurofarma Laboratórios, Ltda., São Paulo, Brazil); c: meglumine
antimoniate, lot  0595L061 (Rhodia Farma, Ltda., São Paulo,
Brazil)
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ing osmolarity of at least ten different lots of meglumine
antimoniate. Lower pH could explain in part the local skin
reactions at the injection site but do not explain the sys-
temic toxicity manifested as generalized rash.
Our results together with the reported analysis of the
reactions observed with other two lots of the drug pro-
duced by Eurofarma Laboratórios Ltda., São Paulo, Brazil
confirming heavy metal contamination (Brazilian Minis-
try of Health 2001), indicates that the unusual frequency
of cutaneous reactions observed in group A patients could
be attributed to heavy metal contamination.
The use of drug salts from dubious origin could ex-
plain the contamination with heavy metals despite good
manufacturing practices during the dilution process. Our
data raise the urgent need to establish stringent criteria
for quality control of pentavalent antimonials including
the inspection of sources of chemical supplies. Recent
report of successful treatment of visceral leishmaniasis in
Kenya using a cheaper generic sodium stibogluconate
produced following good manufacturing practices shows
that the production of generic drugs of adequate quality
could be an achievable goal (Moore et al. 2001). However
the unexpected high frequency of rash episodes observed
in both intervention groups in that research deserves more
attention to identify the causes of that phenomenon. Pen-
tavalent antimonial characteristics are the antithesis of
the ideal drug profile for the treatment of any disease, the
situation is the worst possible if we consider that leish-
maniasis affects mainly poor people living in less devel-
oped countries where health services usually show pre-
carious conditions. Until the development of cheaper oral
medications with minor toxicity, the important next step
should be the construction of a surveillance system for
adverse events observed with pentavalent antimonials
aiming the early detection of the more dangerous forms of
toxicity to avoid potentially lethal outcomes.
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